ProNAi Therapeutics, Inc. (NASDAQ:SRRA) – Stock analysts at Jefferies Group upped their FY2017 earnings per share estimates for ProNAi Therapeutics in a report released on Thursday. Jefferies Group analyst M. Raycroft now forecasts that the biotechnology company will post earnings of ($0.85) per share for the year, up from their prior estimate of ($0.86). Jefferies Group currently has a “Buy” rating on the stock. Jefferies Group also issued estimates for ProNAi Therapeutics’ FY2019 earnings at ($0.83) EPS, FY2020 earnings at ($0.87) EPS and FY2021 earnings at ($1.10) EPS.

Other analysts also recently issued reports about the company. Zacks Investment Research downgraded ProNAi Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday, October 26th. ValuEngine upgraded ProNAi Therapeutics from a “strong sell” rating to a “sell” rating in a report on Friday, September 1st. Two research analysts have rated the stock with a sell rating and three have issued a buy rating to the company. ProNAi Therapeutics presently has an average rating of “Hold” and a consensus price target of $4.00.

ILLEGAL ACTIVITY WARNING: “ProNAi Therapeutics, Inc. to Post FY2017 Earnings of ($0.85) Per Share, Jefferies Group Forecasts (SRRA)” was first published by Watch List News and is the property of of Watch List News. If you are accessing this story on another website, it was illegally copied and reposted in violation of United States and international copyright law. The original version of this story can be viewed at

Shares of ProNAi Therapeutics (NASDAQ:SRRA) opened at $1.93 on Monday. ProNAi Therapeutics has a twelve month low of $1.10 and a twelve month high of $2.25.

ProNAi Therapeutics (NASDAQ:SRRA) last released its quarterly earnings data on Wednesday, November 8th. The biotechnology company reported ($0.19) EPS for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.03.

A hedge fund recently bought a new stake in ProNAi Therapeutics stock. FMR LLC purchased a new stake in ProNAi Therapeutics, Inc. (NASDAQ:SRRA) in the 1st quarter, according to its most recent filing with the SEC. The institutional investor purchased 197,100 shares of the biotechnology company’s stock, valued at approximately $302,000. FMR LLC owned approximately 0.38% of ProNAi Therapeutics at the end of the most recent quarter. Institutional investors and hedge funds own 55.65% of the company’s stock.

About ProNAi Therapeutics

Sierra Oncology, Inc, formerly ProNAi Therapeutics, Inc, is a clinical-stage drug development company. The Company’s lead drug candidate, SRA737, is orally bioavailable small molecule inhibitor of Checkpoint kinase 1 (Chk1), a key cell cycle checkpoint and central regulator of the deoxyribonucleic acid (DNA) Damage Response (DDR) network.

Earnings History and Estimates for ProNAi Therapeutics (NASDAQ:SRRA)

Receive News & Ratings for ProNAi Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProNAi Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.